MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases

Ying Meng, Raymond M. Reilly, Rossanna C. Pezo, Maureen Trudeau, Arjun Sahgal, Amit Singnurkar, James Perry, Sten Myrehaug, Christopher B. Pople, Benjamin Davidson,

Science Translational Medicine · 2021 · 220 citations · 27 references

Concepts

Abstract

In-BzDTPA-NLS-trastuzumab SPECT imaging. The standardized uptake value ratio (SUVR) of MRgFUS-treated lesions increased, on average, by 101 ± 71%, compared to −18 ± 26% in control lesions. MRgFUS enhanced drug uptake in 87 ± 17% of sonicated voxels (>20% increase in SUVR), with up to a 450% voxel-wise increase detected. Control lesions had 8 ± 8% voxels with >20% increase in SUVR. With treatment, unidimensional tumor measurements decreased by 19 ± 12%. This study provides first-in-human evidence of noninvasive, spatially targeted monoclonal antibody delivery across the BBB using MRgFUS, demonstrating the promise of this technology for a broad range of CNS diseases.

References

27